These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 26242693)

  • 1. The only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level: Commentary.
    Hutchinson M
    Mult Scler; 2015 Sep; 21(10):1242-3. PubMed ID: 26242693
    [No Abstract]   [Full Text] [Related]  

  • 2. The only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level-NO.
    Arrambide G; Espejo C; Tintore M
    Mult Scler; 2015 Sep; 21(10):1240-2. PubMed ID: 26242692
    [No Abstract]   [Full Text] [Related]  

  • 3. The only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level - YES.
    Salzer J
    Mult Scler; 2015 Sep; 21(10):1239-40. PubMed ID: 25828757
    [No Abstract]   [Full Text] [Related]  

  • 4. Neurofilament Light: A Dynamic Cross-Disease Fluid Biomarker for Neurodegeneration.
    Zetterberg H
    Neuron; 2016 Jul; 91(1):1-3. PubMed ID: 27387643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New movements in neurofilament transport, turnover and disease.
    Barry DM; Millecamps S; Julien JP; Garcia ML
    Exp Cell Res; 2007 Jun; 313(10):2110-20. PubMed ID: 17451679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamics of the neuronal intermediate filaments.
    Okabe S; Miyasaka H; Hirokawa N
    J Cell Biol; 1993 Apr; 121(2):375-86. PubMed ID: 8468352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The amount of neurofilaments aggregated in the cell body is controlled by their increased sensitivity to trypsin-like proteases.
    Fasani F; Bocquet A; Robert P; Peterson A; Eyer J
    J Cell Sci; 2004 Feb; 117(Pt 6):861-9. PubMed ID: 14762113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spontaneous perikaryal neurofilament phosphorylation in the septofimbrial nucleus of the rat.
    Klosen P; van den Bosch de Aguilar P
    Neurosci Lett; 1992 May; 139(1):108-13. PubMed ID: 1407676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurofilament protein phosphorylation: topographic regulation and functions.
    Pant HC; Floyd CC; Dosemeci A
    Adv Second Messenger Phosphoprotein Res; 1990; 24():393-8. PubMed ID: 2119648
    [No Abstract]   [Full Text] [Related]  

  • 10. Neurofilament in clinical practice: Is the multiple sclerosis community ready?
    Moccia M; Terracciano D; Brescia Morra V; Castaldo G
    Mult Scler; 2024 May; 30(6):643-645. PubMed ID: 38605490
    [No Abstract]   [Full Text] [Related]  

  • 11. [Regulation of functions of intermediate filaments by protein phosphatases].
    Saito T; Hisanaga S
    Tanpakushitsu Kakusan Koso; 1998 Jun; 43(8 Suppl):996-1003. PubMed ID: 9655956
    [No Abstract]   [Full Text] [Related]  

  • 12. Neurofilament light chain as a marker for cortical atrophy in multiple sclerosis without radiological signs of disease activity.
    Ineichen BV; Moridi T; Ewing E; Ouellette R; Manouchehrinia A; Stawiarz L; Ferreira D; Muehlboeck SJ; Kuhle J; Westman E; Leppert D; Hillert J; Olsson T; Kockum I; Piehl F; Granberg T
    J Intern Med; 2021 Aug; 290(2):473-476. PubMed ID: 33871105
    [No Abstract]   [Full Text] [Related]  

  • 13. Neurofilaments in blood: (Almost) facing clinical application.
    Mielke MM; Otto M
    Neurology; 2017 Nov; 89(21):2126-2127. PubMed ID: 29070663
    [No Abstract]   [Full Text] [Related]  

  • 14. Is CSF neurofilament light chain measurement relevant for MS?
    Matsui M
    Neurol Neuroimmunol Neuroinflamm; 2020 Nov; 7(6):. PubMed ID: 32928895
    [No Abstract]   [Full Text] [Related]  

  • 15. The protein phosphatase inhibitor okadaic acid increases axonal neurofilaments and neurite caliber, and decreases axonal microtubules in NB2a/d1 cells.
    Shea TB; Paskevich PA; Beermann ML
    J Neurosci Res; 1993 Aug; 35(5):507-21. PubMed ID: 8397305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From neurofilament research to multiple sclerosis clinical practice: Where do we stand?
    Bodini B; Calabresi PA
    Neurology; 2017 Feb; 88(9):816-817. PubMed ID: 28148634
    [No Abstract]   [Full Text] [Related]  

  • 17. Ongoing Axonal Injury in Chronic Active Lesions in Multiple Sclerosis: In Vivo Quantification Using Serum Neurofilament.
    Preziosa P; Schoonheim MM
    Neurology; 2021 Aug; 97(6):257-258. PubMed ID: 34088879
    [No Abstract]   [Full Text] [Related]  

  • 18. Neurofilaments as biomarkers in multiple sclerosis.
    Teunissen CE; Khalil M
    Mult Scler; 2012 May; 18(5):552-6. PubMed ID: 22492131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurofilament in CSF-A biomarker of disease activity and long-term prognosis in multiple sclerosis.
    Soelberg Sorensen P; Sellebjerg F
    Mult Scler; 2016 Aug; 22(9):1112-3. PubMed ID: 27364323
    [No Abstract]   [Full Text] [Related]  

  • 20. Neurofilaments and NFL-TBS.40-63 peptide penetrate oligodendrocytes through clathrin-dependent endocytosis to promote their growth and survival in vitro.
    Fressinaud C; Eyer J
    Neuroscience; 2015 Jul; 298():42-51. PubMed ID: 25862585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.